Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Human interferon alpha derivative and polyethylene glycol modified substance thereof

A technology of PEGylation and interferon α, which is applied in the field of biomedicine, can solve the problems affecting the purity of PEGylation modifications and the low rate of PEGylation modification, and achieve good clinical application prospects, good water solubility, The effect of low antigenicity

Active Publication Date: 2009-08-26
BEIJING SIHUAN PHARMA +1
View PDF0 Cites 7 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0008] Sequence analysis found that the first N-terminus of human interferon α family α1a, α2a and α1b is a cysteine ​​residue, and a disulfide bond is formed between -SH and -SH of Cys 29, so that human interferon The polypeptide molecule of α becomes a coiled spatial configuration. If the amino-terminal residues of the existing human interferon α are modified with PEGylation PEG, the PEGylation modification rate is very low, only up to 2-5 %, and the obtained pegylated modification contains non-amino-terminal modified isomers, which affects the purity of the pegylated modified human interferon alpha

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Human interferon alpha derivative and polyethylene glycol modified substance thereof
  • Human interferon alpha derivative and polyethylene glycol modified substance thereof
  • Human interferon alpha derivative and polyethylene glycol modified substance thereof

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0034] Example 1: gly-gly-gly-gly-gly-IFNα-2a (hereinafter referred to as Gly(5)-IFN

[0035] α) Secreted expression in Pichia pastoris

[0036] 1. Design and acquisition of the target gene:

[0037] The amino acid sequence of IFNα-2a is shown in SEQ ID No.1. After obtaining the cDNA of IFNα-2a through Genebank, the corresponding codons were changed to yeast preference, and the corresponding nucleotide sequence of gly-gly-gly-gly-gly was added to the N-terminus. This CDNA sequence was used in the construction of the pGAPZα expression plasmid (purchased from invitrogen) of Pichia pastoris GS115 (purchased from invitrogen). Secreted expression was achieved after transformation of GS115 host bacteria. Therefore, the enzyme recognition site CTC GAG AAA AGA of KEX2 was added in the design, wherein CTC GAG is the XhoI restriction site. At the same time, a double stop codon TGA TAA and a NotI restriction sequence GCG GCCGC were introduced into the 3' end. The cDNA sequence of IF...

Embodiment 2

[0054] Example 2: Purification of Gly(5)-IFNα

[0055] The first step: cationic gel column (CM Sepharose F.F. gel purchased from Amersham Biosciences) chromatography:

[0056] Acetate buffer with pH 3.8-4.6 was used for column loading and elution, and electrophoresis monitoring was used to collect target objects. Then, the target substance was dialyzed with a pH 7.5-8.5 Tris-HCl buffer solution.

[0057] The second step: anion gel column (DEAE Sepharose F.F. gel purchased from Amersham Biosciences) chromatography:

[0058] The pH7.5-8.5 Tris-HCl buffer solution is used for column loading and elution, and the target substance is collected. Then dialyze the target substance with pH 7.5-8.5 phosphate buffer solution.

Embodiment 3

[0059] Example 3: Preparation and purification of PEG-coupling modified samples

[0060] 1. Dialyze the Gly(5)-IFNα sample obtained in Example 1 with phosphate buffer (pH 6.0), and then add ALD-PEG 40KD (purchased from Beijing Jiankai Technology Co., Ltd.) with a molar ratio of 1:3 The modification is carried out at 2-15°C, and the reaction time is 40 hours. The obtained modified sample was tested by SDS-PAGE. The test results showed that after PEG coupling modification, the molecular weight increased from the original 19,000 Daltons to nearly 90,000 Daltons, and the modification rate reached about 60%, and the target compound was obtained mPEG-Gly(5)-IFNα.

[0061] 2. Purification of mPEG-Gly(5)-IFNα:

[0062] The mPEG-Gly(5)-IFNα was adjusted with acetate buffer (pH 4.0-5.0) to terminate the reaction, and purified on a cationic gel column SP Sepharose F.F. gel column. Elute with NaCl (0.15M) solution to collect the target substance with a purity of over 95%. The result i...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention discloses human interferon alpha derivative and polyethylene glycol modified substance thereof. The human interferon alpha derivative provided by the present invention is formed by connecting 4-7 glycines on amino end of human interferon alpha. The polyethylene glycol modified substance of the human interferon alpha derivative is formed by connecting polyethylene glycol to the amino end of the human interferon alpha derivative through amido bond. The invention also provides a preparation method for the polyethylene glycol modified substance of the human interferon alpha derivative and use thereof in treating and preventing viral infection or tumor medicament. The polyethylene glycol modified substance of the human interferon alpha derivative does not contain non-amino end modified isomer, and has purity of more than 95%, long in vivo retention time, and widely clinic application prospect.

Description

technical field [0001] The invention relates to the technical field of biomedicine, in particular to human interferon alpha derivatives, pegylated modified products of human interferon alpha derivatives and their preparation and application. Background technique [0002] Human interferon (interferon, IFN) is a kind of active protein with broad-spectrum anti-virus, anti-proliferation and immune regulation functions in the body, and it is one of the earliest cytokines used in clinical treatment. Human interferon can be divided into three types, namely human interferon-α, human interferon-β, and human interferon-γ, and can be further divided into several subtypes according to the amino acid sequence of each type of IFN. A large number of clinical studies have proved that human interferon-α is an important anti-tumor and anti-viral drug. At present, the most widely used clinically in my country is mainly recombinant human interferon α-1a, α-2a and α-1b. [0003] Human interfer...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): C07K14/56C12N15/21C12N15/63C07K17/08A61K38/21A61K47/48A61P31/12A61P35/00A61K47/64
Inventor 夏中宁吴然张丽杰
Owner BEIJING SIHUAN PHARMA
Features
  • Generate Ideas
  • Intellectual Property
  • Life Sciences
  • Materials
  • Tech Scout
Why Patsnap Eureka
  • Unparalleled Data Quality
  • Higher Quality Content
  • 60% Fewer Hallucinations
Social media
Patsnap Eureka Blog
Learn More

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2025 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com